New candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEX TM design to target prostate and multiple solid tumor cancers by simultaneously engaging tumor antigens, T cells, and ...
Bacteria, parasites, viruses—the immune system tackles them all. At the front line of the human immune response are cells called macrophages, which are responsible for correctly identifying intruders ...
Many vaccines work by introducing a protein to the body that resembles part of a virus. Ideally, the immune system will produce long-lasting antibodies recognizing that specific virus, thereby ...
SEATTLE, WASHINGTON / ACCESS Newswire / November 10, 2025 / Aptevo Therapeutics ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company advancing differentiated ...
Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) is a rare disease that affects the filtering units in your kidneys (glomeruli). There are many types of glomerular diseases.
A groundbreaking study, led by Professor Kyemyung Park and his research team in the Graduate School of Health Science and Technology and the Department of Biomedical Engineering at UNIST has shed ...
Aptevo's CD3-engaging portfolio is anchored by mipletamig, a first-in-class CD123 x CD3 bispecific currently being evaluated in RAINIER, a Phase 1b/2 trial for frontline AML. In total, mipletamig has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback